South Korea · Delayed Price · Currency is KRW T Scientific Statistics
Total Valuation
T Scientific has a market cap or net worth of KRW 33.49 billion. The enterprise value is 26.55 billion.
| Market Cap | 33.49B |
| Enterprise Value | 26.55B |
Important Dates
The last earnings date was Thursday, May 21, 2026.
| Earnings Date | May 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
T Scientific has 14.25 million shares outstanding. The number of shares has increased by 2.54% in one year.
| Current Share Class | 14.25M |
| Shares Outstanding | 14.25M |
| Shares Change (YoY) | +2.54% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 0.20% |
| Float | 9.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.92 |
| PB Ratio | 0.20 |
| P/TBV Ratio | 0.20 |
| P/FCF Ratio | 52.47 |
| P/OCF Ratio | 46.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.82, with an EV/FCF ratio of 41.60.
| EV / Earnings | -20.73 |
| EV / Sales | 0.73 |
| EV / EBITDA | 20.82 |
| EV / EBIT | 100.44 |
| EV / FCF | 41.60 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.95 |
| Quick Ratio | 1.73 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 5.18 |
| Debt / FCF | 10.36 |
| Interest Coverage | 0.34 |
Financial Efficiency
Return on equity (ROE) is -1.03% and return on invested capital (ROIC) is 0.18%.
| Return on Equity (ROE) | -1.03% |
| Return on Assets (ROA) | 0.09% |
| Return on Invested Capital (ROIC) | 0.18% |
| Return on Capital Employed (ROCE) | 0.14% |
| Weighted Average Cost of Capital (WACC) | 4.14% |
| Revenue Per Employee | 519.52M |
| Profits Per Employee | -18.29M |
| Employee Count | 70 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 105.82 |
Taxes
| Income Tax | -3.25B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.30% in the last 52 weeks. The beta is -0.21, so T Scientific's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | -45.30% |
| 50-Day Moving Average | 2,950.20 |
| 200-Day Moving Average | 4,562.23 |
| Relative Strength Index (RSI) | 35.96 |
| Average Volume (20 Days) | 110,111 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, T Scientific had revenue of KRW 36.37 billion and -1.28 billion in losses. Loss per share was -89.87.
| Revenue | 36.37B |
| Gross Profit | 11.00B |
| Operating Income | 264.33M |
| Pretax Income | -4.85B |
| Net Income | -1.28B |
| EBITDA | 1.28B |
| EBIT | 264.33M |
| Loss Per Share | -89.87 |
Balance Sheet
The company has 13.45 billion in cash and 6.61 billion in debt, with a net cash position of 6.84 billion or 480.25 per share.
| Cash & Cash Equivalents | 13.45B |
| Total Debt | 6.61B |
| Net Cash | 6.84B |
| Net Cash Per Share | 480.25 |
| Equity (Book Value) | 170.21B |
| Book Value Per Share | 11,951.27 |
| Working Capital | 14.13B |
Cash Flow
In the last 12 months, operating cash flow was 720.57 million and capital expenditures -82.42 million, giving a free cash flow of 638.15 million.
| Operating Cash Flow | 720.57M |
| Capital Expenditures | -82.42M |
| Depreciation & Amortization | 1.01B |
| Net Borrowing | 3.27B |
| Free Cash Flow | 638.15M |
| FCF Per Share | 44.78 |
Margins
Gross margin is 30.25%, with operating and profit margins of 0.73% and -3.52%.
| Gross Margin | 30.25% |
| Operating Margin | 0.73% |
| Pretax Margin | -13.33% |
| Profit Margin | -3.52% |
| EBITDA Margin | 3.51% |
| EBIT Margin | 0.73% |
| FCF Margin | 1.75% |
Dividends & Yields
T Scientific does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.54% |
| Shareholder Yield | -2.54% |
| Earnings Yield | -3.82% |
| FCF Yield | 1.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 10, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 10, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
T Scientific has an Altman Z-Score of 1.16 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 5 |